InstrumentCube
Products

Home/News/Look at "AI + high-precision characterization" to increase the "stability" of China's innovative drugs overseas
Company News

Look at "AI + high-precision characterization" to increase the "stability" of China's innovative drugs overseas

Instrument.com.cn Mar 10, 2026

Keywords: AI|Protein characterization|Formulation optimization|Innovative drugs overseas|nanoDSF|DLS

picture



Preface Background

At the beginning of 2026, China’s innovative drug license-out transactions have reached a breakthrough$53 billion, Innovent Biologics and Eli Lilly reached an $8.5 billion cooperation, Rongchang Biologics$650 millionMajor cooperations such as down payments have been implemented one after another... Behind these figures, a clear industry trend is reflected: China's innovative drugs are moving from following to global pacesetters and some leading the way.

picture

However, do you also feel double pressure under the waves of sea?
At the 2026 JPM conference, Chinese pharmaceutical companies have transformed from onlookers to core participants. It can be seen that multinational pharmaceutical companies' requirements for assets have been upgraded from "me-too" to best-in-class, and strict standards have been put forward for drug developability; and the formulation development of innovative molecules such as bisAbs and ADCs is becoming a key bottleneck restricting IND filings and BD transactions. current,China's pharmaceutical industry is shifting to a new stage of quality-benefit and systematic innovation。

What this means for formulation development?

What is delivered to overseas partners is no longer just “storable molecules”, but complete solutions with clear stability fingerprints, clear developability boundaries, and large-scale production. License-out is moving from “selling young people” to in-depth joint development.Request pharmaceutical companiesAbility to develop global formulations at an early stage。



Case interpretation: Intelligent development at the same pace as "innovation"

Recently, an article fromNovo NordiskandETH ZurichScientists published a study in Molecular Pharmaceutics showing us the results fromAcademia and Industrytop teamwork,Jointly develop a new paradigm for formulation development that perfectly matches the current industry pace.。

picture

Research Difficulties

Confronted in this study was a “hard mode” model—bococizumab-IgG1, aMonoclonal antibodies known to be difficult to drug,This is what domestic pharmaceutical companies doDual antibodies, ADCThe dilemmas encountered when--Their goal is not to optimize a single metric, but to simultaneously balance three key attributes:
 1. Thermal stability (Tm):Related to the structural integrity of the antibody
 2. Colloidal stability (kD): Predict its aggregation trend
 3. Interface stability:Assess the stress risks in its production and transportation
It's like unlocking three locks at the same time, and the password consists of six variables (pH, concentration of various excipients, etc.), among which there are complex nonlinear interactions.

Limitations of traditional DoE:The more variables there are, the experimental volume increases exponentially, the cycle is long, and it is easy to fall into local optimality.It is completely unable to keep up with the rapid introduction of innovative drugs to overseas markets and the pace of global competition.。

Breakthroughs from this research:AI Bayesian optimization + closed-loop system with high-precision characterization = amazing results:


Extremely efficient: With only 33 experiments, the highly optimized formula area was successfully locked.


Clear Insight: Quantifying the Effect of pH on Thermal Stability(Tm)and colloidal stability (kD)The opposite effect of provides data support for the final trade-off decision.


Industrially feasible: Taking into account production constraints such as osmotic pressure and pH, it can be implemented directly.



What does this mean for your team?

Driven by experience → driven by data

Use machine algorithms to explore the recipe space, break through homogeneous competition, and use differentiated data to impress overseas partners.

Optimize from a single point → global balance

Clearly seeing the complex network of relationships between different stabilities and different excipients allows you to make wise trade-offs in the early stages of development. This is especially important for projects preparing for overseas licensing, because once they enter the BD due diligence stage, any developability flaws may become a bargaining chip to lower the price.

From long trial and error → precise navigation

The cycle is shortened from months to weeks, freeing the team from repeated experiments and investing in more creative work, strengthening "China's R&D efficiency", which is also one of China's most valued advantages by global pharmaceutical giants.                                                                  



Research inspiration

What technology supports this “intelligent navigation”?

The upper limit of any AI algorithm is determined by data quality. A crucial cornerstone for the success of this research is accurate and efficient biophysical characterization.The researchers clearly stated,themUsing nanoDSF+DLS technologyObtain high reliability Tm、kDData, both technologies come fromPrometheus Panta, a protein stability analysis platform,Its core advantages:High-precision protein thermal stability and colloidal stability data can be obtained quickly and label-free with only a very small amount of sample.。Panta's integrated design makes it possible to complete DLS and nanoDSF measurements successively on the same sample tube and the same equipment, greatly simplifying the workflow and reducing sample requirements and errors.

picture
Protein stability analysis platformPrometheus Panta
"Dedicated to provide accurate guarantee for biopharmaceuticals going overseas"

In 2026, China's innovative pharmaceutical industry will undergo a profound transformation, allowing overseas licensing transactions to evolve from single product licensing to technology export, platform co-construction, and global parallelization. Preparation development should no longer be regarded as a "required procedure" before IND filing, but should become:
· "Stabilizer" that adds value to assets:A solid preparation data package can give you higher value in BD negotiations
· The "booster" to speed up overseas expansion:Developability assessment helps you identify risks in advance and avoid exposing problems later.
· The "display window" of the technology platform:Systematic formulation development capabilities = strong proof of the maturity of the company’s technology platform

If you also wish to:
·Significantly shorten the antibody development cycle and match the pace of innovative drugs going overseas
· Use data to add core chips to BD transactions and liberate team energy
· Build a development platform that is data-driven, predictable, and in line with international standards

Then, the "intelligent optimization workflow" demonstrated in this research is the next direction you need to focus on.

Let us join hands to turn the development of biologics into a precise science that is predictable and optimizable - laying a solid foundation for stability in the globalization journey of China's innovative drugs.


References:
Waibel I, Schneider TN, Fischer FJ, Dumnoenchanvanit P, Kulakova A, Nguyen TD, Egebjerg T, Bertelsen S, Lorenzen N, Arosio P. Bayesian Optimization for Efficient Multiobjective Formulation Development of Biologics. Mol Pharm. 2025 Nov 3;22(11):6636-6645. doi: 10.1021/acs.molpharmaceut.5c00591IF: 4.5 Q1                                                                                                                                                                    

NanoTemper Technologies (Beijing) Co., Ltd.
Main products: Differential Scanning Calorimeter (DSC/DTA), Molecular Interaction Analyzer, Protein Stability Analyzer